"Innovation Pioneer"
In April last year, under the auspices of the State Drug Administration, the "Guiding Principles for the Registration and Review of Recombinant Collagen Wound Dressings" special meeting was held in Beijing, and eight domestic leading recombinant collagen companies gathered together, and the company from Xi'an, Shaanxi Province occupied two seats, one is Juzi Biotech, and the other is Shaanxi Huikang Biotechnology Co., Ltd. (hereinafter referred to as "Huikang Biotech").
If it is said that Juzi Biotech has opened the era of recombinant collagen industrialization in China, then Huikang Biotech has pioneered I&III. chimeric recombinant double collagen in 2010 with a forward-looking vision and strong innovation ability, taking the lead in opening the door to the era of recombinant double collagen in China and leading the industry for more than 10 years.
Qingyan noticed that now, this 23-year-old Chinese bioscience veteran enterprise with deep accumulation in the field of recombinant collagen and peptides is entering the beauty and skin care track strongly, injecting new vitality into the current fiercely competitive beauty market.
Behind the 11 years of leadership: the pioneer of recombinant collagen innovation
According to Frost & Sullivan, the market size of recombinant collagen products in China is expected to increase from 18.5 billion yuan in 2022 to 108.3 billion yuan in 2027, with a compound annual growth rate of 42.4%.
Especially in the past two years, in the beauty track, the application of recombinant collagen ingredients has also ushered in a boom, and L'Oreal, Proya and other leading beauty companies at home and abroad have applied recombinant collagen to their products.
In fact, as one of the few Chinese companies that has taken the lead in breaking through the whole chain of production, education and research, the application boom of recombinant collagen is inseparable from the enterprising and bold innovation of recombinant collagen companies, and Huikang Biotech is one of the leaders.
For example, in the past two years, as an important innovation in the recombinant collagen track, many beauty and skin care brands have added recombinant double collagen as the selling point of their products, while Huikang Biotech has completed technical research as early as 2010, leading the industry for more than 10 years, and can be called the "leader" of the recombinant double collagen market.
At that time, Huikang Biotech creatively fused the functional regions of type I collagen and type III collagen (the ratio of type I and type III was 0.96:1) through genetic engineering and synthetic biotechnology, overcame the problem that type I and type III could not be supplemented at the same time, and successfully developed the first I.&III. chimeric recombinant double collagen, and obtained the national invention patent ZL 201010527766.7 "Genetically recombinant human collagen fusion peptide and its preparation method and application".
In the past ten years, Huikang Biotech can be called a "geek" in the research and development of recombinant collagen, and has launched a number of high-tech recombinant collagen innovations.
▍The evolutionary history of Huikang collagen
Only two years after the creation of the "gene code I.&III. double collagen", Huikang Biotech has developed a national patent type I recombinant human collagen and epidermal growth factor EGF dual expression system, which realizes the production of two proteins at one time and greatly improves the production efficiency.
In 2016, Huikang Biotech launched the first fully human "Smart Collagen SAC, "Super-Aqua-Collagen"" in China, and obtained the national invention patent, which has the advantages of high purity, high activity, high stability, small molecular weight, and easy absorption and utilization by the skin.
In this regard, Huikang Biotech told Qingyan, "In the future, Huikang will design a variety of 'singularity' collagen with excellent characteristics based on the synthetic biology intelligent manufacturing platform - 'IT+BT'."
It can be seen that in the field of recombinant collagen, Huikang Biotech has been "traveling" to the fullest, and has continuously broken through technical problems with persistent focus and creative thinking. Among them, the weighty papers and heavy patent certificates are the vivid footnotes to the research and development of Huikang Bio's recombinant collagen.
Up to now, Huikang Bio's recombinant collagen and collagen research and development results have been published in many important journals at home and abroad.
At the same time, from 2010 to the present, Huikang Biotech has obtained a number of national invention patents in the field of recombinant collagen, such as "A Purification Method for Recombinant Human Collagen", "Recombinant Human Collagen Stock Solution, Dressings and Their Preparation Methods".
If you don't accumulate steps, you can't make thousands of miles. After more than ten years, Huikang Biotech has become one of the enterprises with the deepest research accumulation of recombinant collagen in China, and continues to invest in the industrialization of recombinant collagen and technical research, providing a steady stream of technical driving force for the industry.
Blockbuster to build "China peptide library"
Climbing the "peak" of peptide innovation
Scientists have predicted that "the 21st century is the century of polypeptides", which undoubtedly reflects the broad application prospects of polypeptides. For Huikang Biotech, peptides and recombinant collagen are like the "two wings" of its research and development, helping Huikang Biotech continue to climb the peak of scientific research.
Qingyan noticed that the representative achievement of Huikang Biotechnology in the field of peptides is the creation of the "China Peptide Library".
According to relevant research, the mutual recognition, interaction and mutual balance between protein molecules in the living body maintain the health of the body, and once this balance is broken, it is a disease. To re-establish equilibrium, it is critical to find a small polypeptide composed of several key residues, epitope peptides.
In November 2018, with firm confidence, Huikang Biotech officially launched the "China Peptide Library" project, aiming to build a parallel peptide library containing 175,000 sequences with accurate sequences, and screen various functional active peptides through a large number of unknown active peptide information contained in it, so as to provide innovative active peptide products required by pharmaceutical, cosmetics and other industries.
At that time, Huikang's bold initiative was noticed by Nature Review: Drug Discovery, a subsidiary of the British Nature Publishing Group, which made a detailed report on the "China Skin Bank" project.
It is reported that the Chinese peptide library can be combined with any detection method to form a large-scale, low-cost, and rapid lead epitope peptide screening system, and provide raw material supply, formula development, and technical support, so as to reduce the product development cycle, path and cost on a large scale, and promote original innovation in the industry.
After more than 1,800 days and nights, up to 130 million yuan of investment, "China Peptide Bank", as a key support project of the provincial Ministry of Science and Technology, has opened the peptide library screening platform to the outside world, and will become a treasure trove of resources shared by all mankind in the future.
In addition to the creation of China's peptide library, Huikang Biotech also has a deep research accumulation in peptide raw materials. For example, the scientific research results of "liquid phase synthesis of hexapeptide" jointly cooperated by the R&D personnel of Huikang Biotechnology were published as a cover article in I&EC Research, one of the three authoritative international chemical journals, which attracted the attention of the international academic community.
▍《I&EC Research》杂志
In the field of intellectual property, Huikang Biotech has always adhered to a rigorous attitude and innovative spirit. As of April 2024, Huikang Biotech has obtained 162 patents and 668 registered trademarks, providing strong support for brand development through its unique patents, trademarks and core technology advantages, relying on recombinant collagen and active peptide technology platforms.
In addition, Huikang Biotech specially selects the polypeptide raw material matrix with palmitoyl pentapeptide-4, tripeptide-1 copper, nonapeptide-1 and acetyl hexapeptide-8 as advantageous raw materials for cosmetics marketing and in-depth application.
With years of exploration in the field of peptides, Huikang Biotech has grown into a "peptide leader" in China, and provides a strong raw material "engine" for its long-term development in the beauty and skin care track.
Strong entry into the beauty and skin care track
Leading the way in recombinant collagen standardization
Today, Huikang Biotech has taken a leading position in the two major fields of peptides and recombinant collagen, and behind the blockbuster achievements comes from Huikang Biotech's continuous investment in research and development. At present, Huikang Biotech has established 3 bases, 5 centers and 14 experimental platforms, of which the scientific research team accounts for 37% of the company's personnel.
At the same time, in the face of the lack of standardization in the market of recombinant collagen and other raw materials, Huikang Biotech also actively participates in the formulation of industry standards and leads the healthy development of the industry. At present, Huikang Biotech has participated in the drafting of many industry group standards such as "Transdermal Absorption Determination Method for Recombinant Collagen", "Quality Requirements and Efficacy Evaluation Methods for Recombinant Collagen Raw Materials", and "Synthetic Polypeptides for Cosmetic Raw Materials".
In recent years, Huikang Biotech has also made frequent efforts in cosmetics production and brand building, and has achieved good market response, becoming a dark horse that cannot be ignored in the effective skin care market.
For example, Ruxin Skin, a peptide technology skin care brand under Huikang Biotech, received an enthusiastic response as soon as it was launched. At present, Ruxin Beauty has launched a number of popular products such as Hexapeptide Wrinkle Smoothing and Plumping Eye Serum, Bifida Yeast Blue Copper Peptide Essence Oil, Collagen Ampoule Essence Mask, Hexapeptide Firming Mask, etc., and its efficacy has been widely praised by the industry.
Among them, Ruxin Skin Six Peptide Firming Mask adopts a newly upgraded "Anti-Aging Matrix", which is specially researched by Huikang Biotechnology, and adopts the form of eye mask + mask in one, which can achieve exogenous anti-aging and internal replenishment, which can be described as an "Anti-aging Mask with Remarkable Effect";
▍Ru Xin Beauty Skin Six Peptide Wrinkle Plumping Eye Tail Serum, Ru New Beauty Skin Six Peptide Firming Mask
Nowadays, the recombinant collagen track is still in a period of rapid development, with the launch of more high-quality products and the enhancement of brand promotion, the future will usher in a greater outbreak, and the application of peptide raw materials in the cosmetics market is also gradually getting better, which means that Huikang Biotechnology, which has already had a layout on the raw material side and the brand side, holds "multiple trump cards" and will become an important force that cannot be ignored in the beauty market.